Close Menu

NEW YORK (GenomeWeb) – Invivoscribe Technologies announced today that it has submitted a pre-market approval application with Japan's Pharmaceutical and Medical Devices Agency, as well as a panel track supplement to the US Food and Drug Administration for its LeukoStrat CDx FLT3 Mutation assay.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.